During Alpha-1 Awareness Month, OSIC founding member CSL Behring shares three inspiring stories from the Alpha-1 Antitrypsin Deficiency community, one of which is a profile of OSIC’s research initiatives in this space.
Executive Director Elizabeth Estes discussed OSIC’s progress in developing biomarkers for rare lung disease as a result of collaboration between academia, industry and philanthropy.
OSIC is mentioned in this research.
Data from the OSIC Data Repository was used to conduct this research.
Data from the OSIC Data Repository was used to conduct this research.
Data from the OSIC Data Repository was used to conduct this research.
Executive Director Elizabeth Estes shared insights on how robust clinical data curation, global normalization, and advanced data power can drive radical progress in drug development for fibrosing lung diseases.
Data from the OSIC Data Repository was used to conduct this research.
Data from the OSIC Data Repository was used to conduct this research.
Data from the OSIC Data Repository was used to conduct this research.
Data from the OSIC Data Repository was used to conduct this research.
OSIC is mentioned in this research.
Data from the OSIC Data Repository was used to conduct this research.
Dr. Kevin Brown and Dr. Simon Walsh discussed recent developments in machine learning algorithms using the OSIC Cloud Data Repository during this Industry Theater presentation.
Data from the OSIC Data Repository was used to conduct this research.
OSIC members discuss how quantitative CT software has huge potential to develop imaging biomarkers to improve the management of fibrosing ILDs, but optimizing their adoption will require technical and societal challenges to be addressed.
Data from the OSIC Data Repository was used to conduct this research.
OSIC is mentioned in this research.
Executive Director Elizabeth Estes and Pam Factor-Litvak, PhD, associate dean for research resources at Columbia University Mailman School of Public Health, discussed “Open-Source as a Model to Advance Public Health Research.”
Executive Director Elizabeth Estes, Melissa Leichter of Novo Nordisk, and Panna Sharma of Lantern Pharma Inc. discussed the potential of using AI and machine learning to treat rare diseases.
Data from the OSIC Data Repository was used to conduct this research.
Data from the OSIC Data Repository was used to conduct this research.
Data from the OSIC Data Repository was used to conduct this research.
OSIC is mentioned in this research.
Data from the OSIC Data Repository was used to conduct this research.
|
What
All
When
November 2024
|